Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;8(3):91-165.
doi: 10.1016/j.kisu.2018.06.001. Epub 2018 Sep 19.

KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group

KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. Kidney Int Suppl (2011). 2018 Oct.
No abstract available

PubMed Disclaimer

Figures

None
Prognosis of CKD by GFR and albuminuria category
Figure 1
Figure 1
Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease (CKD) G4–G5D and kidney transplant recipients (KTRs), by hepatitis C virus (HCV) genotypea. Duration of therapy for all above regimens is usually 12 weeks but readers should consult Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver guidelines for latest guidance. aWe recommend that CKD patients with glomerular filtration rates (GFRs) ≥ 30 ml/min per 1.73 m2 (CKD G1T–G3bT) be treated with any licensed DAA regimen. bThere is little published evidence to guide treatment regimens in KTRs with GFR < 30 ml/min per 1.73 m2 (CKD G4T–G5T). Regimens in KTRs should be selected to avoid drug–drug interactions, particularly with calcineurin inhibitors. cBased on Reau et al.dAs suggested in AASLD guidelines (https://www.hcvguidelines.org/). CKD G, chronic kidney disease (GFR category); HD, hemodialysis; n/a, no data or evidence available; PD, peritoneal dialysis.
Algorithm 1
Algorithm 1
Treatment scheme for chronic kidney disease (CKD) G1–G5D. Recommendation grading is provided for each specific treatment regimen and hepatitis C virus (HCV) genotype. CKD G, chronic kidney disease, GFR category; DAA, direct-acting antiviral; GFR, glomerular filtration rate; NAT, nucleic acid testing.
Algorithm 2
Algorithm 2
Treatment scheme for kidney transplant recipients (KTRs). Recommendation grading is provided for each specific treatment regimen and hepatitis C virus (HCV) genotype. Chronic kidney disease (CKD) G, CKD glomerular filtration rate (GFR) category (suffix T denotes transplant recipient); NAT, nucleic acid testing.
Algorithm 3
Algorithm 3
Proposed strategy in a hepatitis C virus (HCV)–infected kidney transplant candidate. SKLT, simultaneous kidney-liver transplantation.
Figure 2
Figure 2
Search yield. AASLD, American Association for the Study of Liver Diseases; ASN, American Society of Nephrology; CKD, chronic kidney disease; GL, guideline; HCV, hepatitis C virus; KDIGO HCV CPG, Kidney Disease: Improving Global Outcomes hepatitis C virus clinical practice guideline.
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
See this image and copyright information in PMC

Comment in

References

    1. Wirtz V.J., Hogerzeil H.V., Gray A.L. Essential medicines for universal health coverage. Lancet. 2017;389:403–476. - PMC - PubMed
    1. The Lancet Gastroenterology Hepatology Access to HCV treatments: hurdles not barriers. Lancet Gastroenterol Hepatol. 2017;2:1. - PubMed
    1. Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection [e-pub ahead of print]. Hepatology. 10.1002/hep.30046. Accessed July 25, 2018. - DOI - PMC - PubMed
    1. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Available at: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/. Accessed July 27, 2018. - PubMed
    1. Bergman S., Accortt N., Turner A. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45:684–689. - PubMed